Leukemia, B-cell Clinical Trial
Official title:
Pilot Study of the Efficacy and Safety of Cluster of Differentiation Antigen 19 (CD19) /Cluster of Differentiation Antigen 22 (CD22) CART in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
This is a single center, open-label ,phase 1/2 study to evaluate the safety and efficacy of targeted CD19/CD22 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD19/CD22 positive Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
The patients will receive infusion of CART cells targeting CD19 and CD22 to confirm the safety and efficacy of CD19/CD22 CART Cells in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT03605589 -
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
|
Phase 1 | |
| Enrolling by invitation |
NCT02473757 -
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
|
||
| Recruiting |
NCT04649983 -
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT02848911 -
Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL
|
Phase 1 | |
| Terminated |
NCT02518750 -
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
|
Phase 2 | |
| Enrolling by invitation |
NCT03229200 -
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
|
Phase 4 | |
| Recruiting |
NCT04439721 -
γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse
|
Early Phase 1 | |
| Not yet recruiting |
NCT03599375 -
Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia
|
Phase 1 | |
| Recruiting |
NCT02813837 -
Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies
|
N/A | |
| Recruiting |
NCT04271410 -
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03598179 -
XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
|
Phase 2 | |
| Recruiting |
NCT05254743 -
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
|
Phase 3 | |
| Recruiting |
NCT05010564 -
Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)
|
Phase 1 | |
| Recruiting |
NCT03564977 -
CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation
|
N/A | |
| Recruiting |
NCT05362773 -
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT02672501 -
A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06209671 -
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
|
Phase 1 | |
| Recruiting |
NCT03564470 -
Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04271800 -
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01087294 -
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
|
Phase 1 |